Companies / NTI

NEUROTECH INTERNATIONAL LIMITED

ASX:NTIHealth Care Equipment & Services
1.32B shares on issueASX (delayed) · as of 28 July 2026$0.017price · delayed$22.5Mmarket cap · indicative
D
Dilution grade

Runway under 2 quarters; share count grew 30% in 24 months; 2 cash raises in 24 months

Cash runway0.6 quarters of funding
Share-count growth (24m)30.0%
Raise cadence (24m)2 cash raises
Options & rights overhang6.8% of shares
In-the-money supply0.0% of shares
Pending proposed issuesnone

NEUROTECH INTERNATIONAL LIMITED's ordinary share count grew 30.0% between April 2024 and July 2026, to 1.32B shares. The company raised capital twice in that 24-month window for total disclosed proceeds of A$8.0M, most recently a A$4.0M placement in December 2025. Options and rights on issue could convert into 90M new shares, equal to 6.8% of the current share count, with 0% in the money at present and the nearest expiry in December 2027. At the March 2026 quarter the company reported A$1.4M in cash, covering about 0.6 quarters at its recent spending rate. No proposed securities issues (Appendix 3B) are pending.

AI-generated summary of this page's cited filings · updated 28 July 2026
Email me when this grade changes
Alerts are coming soon — this opens a pre-filled email that puts you on the list.
6.8%
Max option dilution
0.0%
ITM option dilution
2
Raises · last 12 months
0.6 qtrs
Cash cover · under 2 quarters

Shares on issue — last 2 years

Ordinary shares on issue
Weekly counts from ASX records. Dots mark cash capital raises. Latest count 1.32B per ASX (delayed) (28 July 2026).
1.10B1.18B1.26BDec 24Sept 25July 26Cash raise · 12 Dec 2025Cash raise · 12 Dec 2025

Cash runway

0.6 qtrs
Less than two quarters of funding at the recent spend rate — near-term funding pressure.
$1.4M available cash at quarter ended 31 Mar 2026 · Runway is computed from Appendix 4C/5B filings and announced raise proceeds.
Paid plan
Cash runway history
Quarterly cash, net spend and cover trend from every Appendix 4C/5B on record up to 31 Mar 2026.
Join the waitlist

Issuance timeline

Latest 5 filings (Appendix 2A quoted issues, 3G unquoted, 3H cancellations)

DateFormSecurityTotal on issue afterSource
21 July 20262A · quoted issueNTI : ORDINARY FULLY PAID1.32BAppendix 2A
13 July 20263G · unquotedNTI : ORDINARY FULLY PAID1.32BAppendix 3G
29 June 20263H · cancellationNTI : ORDINARY FULLY PAID1.32BAppendix 3H
28 Apr 20263H · cancellationNTI : ORDINARY FULLY PAID1.32BAppendix 3H
30 Mar 20262A · quoted issueNTI : ORDINARY FULLY PAID1.32BAppendix 2A
Paid plan
Full issuance history
Every quoted and unquoted issue and cancellation on record, plus unquoted securities (Appendix 4.2).
Join the waitlist

Capital raises

2 cash raises in the last 24 months · 2 in the last 12 months

$4.0M
Placement
12 Dec 2025 ACTIVE
Paid plan
Full raise history
Issue price, discount, brokers, purpose and tranche detail for every raise on record.
Join the waitlist

Pending proposed issues

No proposed issues (Appendix 3B) currently pending.

Options & convertible securities

6.8%
Total overhang · of current shares
0.0%
In the money · at current price
89.5M
Potential new shares
Dec 2027
Nearest expiry
Paid plan
Per-line options & expiry cliffs
Each option line — code, strike, expiry, quantity and ITM value — plus the expiry-cliff chart.
Join the waitlist

Director dealings

DateDirectorTypeSharesOptionsValueSource
24 Apr 2026Robert Maxwell JohnstonSell4.6M1.0M—3Y notice
30 Mar 2026Gerald QuigleyBuy3.6M—$50k3Y notice
30 Mar 2026Anthony FilippisBuy3.6M20.0M$50k3Y notice
Paid plan
Full dealing history
Every change-of-director's-interest notice on record, with direction and consideration.
Join the waitlist

Ownership

Free account
Top-20 holders & substantial holder notices
Top-20 register snapshot and substantial-holder movements, each linked to its source notice.
Sign up free — coming soon

Latest announcements

21 July 2026Secondary Trading Notice
21 July 2026Application for quotation of securities - NTI
15 July 2026$PNeurotech secures $3.15 million R&D tax incentive loan
13 July 2026$PUS FDA clears IND for NTI164
13 July 2026Notification regarding unquoted securities - NTI
12 July 2026Proposed issue of securities - NTI
1 July 2026$PNTI secures Notices of Allowance for US patent applications
29 June 2026Notification of cessation of securities - NTI
28 Apr 2026$PQuarterly Activities/Appendix 4C Cash Flow Report
28 Apr 2026Change of Director's Interest Notice
28 Apr 2026Notification of cessation of securities - NTI
23 Apr 2026Ceasing to be a substantial holder
12 Apr 2026Neurotech to present at Ignite Investment Summit Hong Kong
31 Mar 2026Change of Director's Interest Notice x 4
30 Mar 2026Secondary Trading Notice
30 Mar 2026Application for quotation of securities - NTI
22 Mar 2026Neurotech to present at NWR Virtual Healthcare Conference
17 Mar 2026Corporate Presentation
16 Mar 2026$PNTI initiates First Clinical Site for Phase 3 ASD Trial
12 Mar 2026Results of General Meeting

Headlines link to the source PDFs on the ASX announcements platform. Data as of 28 July 2026.